RGNX 250516 7.50C(RGNX250516C7500) Stock Price Today

US OptionsDetailed Quotes

RGNX250516C7500

Watchlist

1.90
0.000.00%

15min DelayTrading Apr 24 15:20 ET

0.00High0.00Low

Intraday

5D
Daily

News

BofA Securities Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $22
Moomoo News07:31 ET · Ratings
Bank of America Securities Reaffirms Their Buy Rating on RegenXBio (RGNX)
TipRanks06:18 ET · Ratings
Gene Therapy Developers Rise on Comments From FDA's Makary
Seeking AlphaApr 21 13:50 ET
Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price Following 29% Dive
Simply Wall StApr 19 08:21 ET
REGENXBIO Is Maintained at Neutral by Goldman Sachs
Dow JonesApr 17 13:54 ET · Ratings
Goldman Sachs Maintains Regenxbio(RGNX.US) With Hold Rating, Cuts Target Price to $12
Moomoo NewsApr 17 02:39 ET · Ratings

Comments

Lnova

Mar 19 10:31

$Regenxbio (RGNX.US)$
Phase 1/2 new biomarker data to be presented on 03/19/2025
*nfa

Teddy123

Mar 14 13:43

REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates

$Regenxbio (RGNX.US)$
REGENXBIO Advances Gene Therapy Pipeline with FDA Filing, Lands Massive $810M Partnership Deal

Jaguar8

Jan 15 11:45

🔴 Watchlist JANUARY 15,2025, Wednesday. NFA. I won’t be around tomorrow morning.

NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If yo...

Jaguar8

Jan 14 19:47

NEWS

$Regenxbio (RGNX.US)$
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
Tuesday, 14th January at 5:00 am
• REGENXBIO to receive $110 million upfront, potential milestone payments of up to $700 million and meaningful double-digit royalties on net sales, and lead manufacturing
• Nippon Shinyaku to lead commercialization of first potential gene therapies for Mucopolysaccharidosis II (MPS II) and Mucopolysaccharidosis ...